Component: (Network and Table)
Network
00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(http://www.iderapharma.com/role/StatementStatementsOfOperationsAndComprehensiveLoss)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000861838 (http://www.sec.gov/CIK)
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSSPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 
 
 
Alliance revenue
16,199,000  
249,000  
73,000  
Operating expenses:
 
 
 
Research and development
39,824,000  
33,699,000  
27,493,000  
General and administrative
15,132,000  
15,396,000  
11,332,000  
Total operating expenses
54,956,000  
 
49,095,000  
 
38,825,000  
 
Loss from operations
(38,757,000) 
 
(48,846,000) 
 
(38,752,000) 
 
Other income (expense):
 
 
 
Interest income
415,000  
357,000  
66,000  
Interest expense
(80,000) 
(105,000) 
(27,000) 
Foreign currency exchange gain
33,000  
39,000  
71,000  
Net loss
(38,389,000) 
 
(48,555,000) 
 
(38,642,000) 
 
Loss on extinguishment of convertible preferred stock and preferred stock dividends
  
519,000  
Net loss
(38,389,000) 
(48,555,000) 
(38,642,000) 
Basic and diluted net loss per common share (Note 12)
(.30) 
(.42) 
(.47) 
Shares used in computing basic and diluted net loss per common share
127,597,000  
115,092,000  
82,827,000  
Net loss
(38,389,000) 
 
(48,555,000) 
 
(39,161,000) 
 
Other comprehensive gain (loss):
 
 
 
Unrealized gain (loss) on available-for-sale securities
117,000  
(117,000) 
(10,000) 
Other comprehensive loss
117,000  
(117,000) 
(10,000) 
Comprehensive loss
(38,272,000) 
(48,672,000) 
(38,652,000)